SCA Pharma appoints Louis Pace as Chief Financial Officer and Chief Information Officer
SCA Pharma strengthens C-Suite with growth-oriented finance staff
WINDSOR, Conn., July 14, 2022 /PRNewswire/ — SCA Pharma, a nationally recognized leader in the 503B Compounding Pharmaceuticals Outsourcing Industry, which provides quality, service and value to hospitals across the country, today announced the addition of Louis Pace as Chief Financial Officer and Chief Information Officer. Pace has over 30 years of experience overseeing multiple successful private equity-backed companies in functional and P&L leadership roles.
Most recently, Mr. Pace served as Chief Financial Officer at Orchid Orthopedic Solutions, where he successfully led strategy development efforts focused on growth and improving profitability.
“I am delighted to welcome Louis to the team and to work alongside him as we continue to accelerate growth at SCA Pharma,” he said Scott Lucas, CEO of SCA Pharma. “SCA Pharma is committed to providing innovative solutions to our 503B Customers who help healthcare systems manage their drug supply chain and pharmacy operations more efficiently. This evolution requires a more strategic and diversified approach that fits Louis’ background. Louis will lead our finance and accounting teams as well as our IT strategy. He will focus on prioritizing internal and external business opportunities.”
“I look forward to working with the extraordinary team at SCA Pharma. I look forward to building on SCA Pharma’s current success and being part of the company’s future growth,” he said Louis Pace.
Mr. Pace holds an AB in Economics from Harvard University and an MBA from Northwestern Kellogg Graduate School of Management.
About SCA Pharma
SCA Pharma is a nationally recognized leader in the FDA 503B Outsourcing industry specializing in providing the highest quality sterile admixtures and prefilled syringes to pharmacies in hospitals and healthcare facilities. The company serves all therapeutic areas of pharmacy – including critical care, labor and delivery, anesthesia and pain management – and maintains a broad product portfolio, including ready-to-use medicines and medicines for drug shortages.
SOURCE SCA Pharma